# A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)

> **NCT00293254** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 351 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** raltegravir potassium
- **DRUG:** Comparator: placebo

## Key facts

- **NCT ID:** NCT00293254
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2007-10
- **Final completion:** 2011-05
- **Target enrollment:** 351 (ACTUAL)
- **Last updated:** 2017-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00293254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00293254, "A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00293254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*